|
|
Blood, 1 November 2007, Vol. 110, No. 9, pp. 3463-3471.
Prepublished online as a Blood First Edition Paper on July 30, 2007; DOI 10.1182/blood-2006-10-054080.
 Previous Article | Table of Contents | Next Article 
TRANSPLANTATION
Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation
André Tichelli1,
Christoph Bucher1,
Alicia Rovó1,
Georg Stussi1,
Martin Stern1,
Michael Paulussen2,
Jörg Halter1,
Sandrine Meyer-Monard1,
Dominik Heim1,
Dimitrios A. Tsakiris1,
Barbara Biedermann3,
Jakob R. Passweg1, and
Alois Gratwohl1
1 Division of Hematology, University Hospital, Basel;
2 University Children's Hospital (UKBB), Pediatric Hematology/Oncology, Basel;
3 Department of Research, University Hospital, Basel, Switzerland
We assessed incidence and risk factors of cardiovascular events in 265 patients undergoing allogeneic hematopoietic stem-cell transplantation (HSCT) between 1980 and 2000 and who survived at least 2 years. Results were compared with a cohort of 145 patients treated during the same period with autologous HSCT. The median age of patients with allogeneic HSCT at last follow-up was 39 years, and median follow-up was 9 years. Eighteen (6.8%) patients after allogeneic and 3 (2.1%) patients after autologous HSCT experienced an arterial event. The cumulative incidence of first arterial event after allogeneic HSCT was 22.1% (95% CI, 12.0-40.9) at 25 years. The cumulative incidence 15 years after allogeneic HSCT was 7.5% as compared with 2.3% after autologous HSCT. Adjusting for age, risk of an arterial event was significantly higher after allogeneic HSCT (RR 6.92; P =.009). In multivariate analysis, allogeneic HSCT (RR: 14.5; P =.003), and at least 2 of 4 cardiovascular risk factors (hypertension, dyslipidemia, diabetes, obesity) (RR: 12.4; P =.02) were associated with a higher incidence of arterial events after HSCT. Thus, long-term survivors after allogeneic HSCT are at high risk for premature arterial vascular disease. HSCT might favor the emergence of established risk factors, such as hypertension, diabetes, and dyslipidemia.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
G. M. Baerlocher, A. Rovo, A. Muller, S. Matthey, M. Stern, J. Halter, D. Heim, J. Rischewski, A. Gratwohl, and A. Tichelli
Cellular senescence of white blood cells in very long-term survivors after allogeneic hematopoietic stem cell transplantation: the role of chronic graft-versus-host disease and female donor sex
Blood,
July 2, 2009;
114(1):
219 - 222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Armenian and S. Bhatia
Cardiovascular disease after hematopoietic cell transplantation - lessons learned
Haematologica,
August 1, 2008;
93(8):
1132 - 1136.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tichelli, J. Passweg, D. Wojcik, A. Rovo, J.-L. Harousseau, T. Masszi, A. Zander, A. Bekassy, C. Crawley, M. Arat, et al.
Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation
Haematologica,
August 1, 2008;
93(8):
1203 - 1210.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tichelli, A. Rovo, and A. Gratwohl
Late Pulmonary, Cardiovascular, and Renal Complications after Hematopoietic Stem Cell Transplantation and Recommended Screening Practices
Hematology,
January 1, 2008;
2008(1):
125 - 133.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Cardiovascular Disease Following Stem-Cell Transplantation
Journal Watch Oncology and Hematology,
November 20, 2007;
2007(1120):
2 - 2.
[Full Text]
|
|
|
|
|
